|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-22
|
|
pubmed:abstractText |
In clinical trials, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administered concomitantly with first-line cytotoxicity chemotherapy failed to confer a survival benefit to patients with non-small-cell lung cancer (NSCLC). The aim of this study was to test whether paclitaxel followed by gefitinib is superior to other treatment schedules of NSCLC cell lines and to clarify the underlying mechanisms.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
637-46
|
|
pubmed:meshHeading |
pubmed-meshheading:20495920-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20495920-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20495920-Cell Cycle,
pubmed-meshheading:20495920-Cell Line, Tumor,
pubmed-meshheading:20495920-Drug Administration Schedule,
pubmed-meshheading:20495920-Drug Synergism,
pubmed-meshheading:20495920-Humans,
pubmed-meshheading:20495920-Lung Neoplasms,
pubmed-meshheading:20495920-Paclitaxel,
pubmed-meshheading:20495920-Phosphorylation,
pubmed-meshheading:20495920-Quinazolines,
pubmed-meshheading:20495920-Receptor, Epidermal Growth Factor,
pubmed-meshheading:20495920-Signal Transduction
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
|
|
pubmed:affiliation |
Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
